·
·
Health
Research revisits vitamin C's potential in cancer therapy, focusing on high-dose intravenous administration and its effects on tumor cells and patient well-being.
In the 1970s, Linus Pauling and Scottish doctor Ewan Cameron began treating advanced cancer patients with large doses of vitamin C administered intravenously, followed by oral supplements. They reported extended survival and improved quality of life compared to patients who did not receive vitamin C.
Following these claims, the Mayo Clinic conducted two major clinical trials using only oral vitamin C tablets. The results showed no survival benefit for patients taking the vitamin compared to those who did not. This outcome led many in the medical community to dismiss vitamin C as an ineffective cancer treatment.
However, the difference in administration routes was overlooked: Pauling and Cameron used intravenous infusions, while the Mayo Clinic trials relied solely on oral dosing. The body limits absorption of vitamin C from the gut, causing blood levels to plateau regardless of oral dosage.
Intravenous delivery can raise blood vitamin C concentrations to levels tens or hundreds of times higher than oral intake. At these elevated levels, vitamin C acts differently, particularly near tumors. Laboratory studies show that high-dose vitamin C generates hydrogen peroxide, a reactive molecule that damages cells.
Cancer cells, which experience high stress and produce many reactive molecules themselves, have compromised internal defense mechanisms. The hydrogen peroxide produced by high-dose vitamin C can overwhelm these defenses, damaging cancer cells’ DNA and energy systems, leading to their death. Normal cells, under less stress, are more resilient to this effect.
Small clinical trials administering high-dose intravenous vitamin C to patients with difficult-to-treat cancers such as ovarian, pancreatic, and brain tumors have shown that many patients tolerate the treatment without serious side effects. Risks exist, particularly for individuals with kidney problems or certain inherited conditions, making this therapy unsuitable as an over-the-counter wellness product.
Some studies indicate that combining vitamin C infusions with chemotherapy may modestly extend survival or reduce chemotherapy side effects, though results are inconsistent and based on limited data. A consistent finding across trials is improved quality of life, with patients reporting less fatigue, pain, and nausea when vitamin C is added to their treatment regimen.
Beyond direct cytotoxic effects, vitamin C influences enzymes that regulate DNA marking and cell division, as well as cellular responses to low oxygen levels, all of which are relevant to cancer progression. Experimental evidence suggests that high vitamin C levels can reduce tumor aggressiveness and increase sensitivity to treatments. Early research also hints at a possible role in enhancing immune recognition of tumors, though this remains speculative.
Pauling’s promotion of vitamin C as a universal cure was overstated and unsupported by large clinical trials using oral doses. Nevertheless, his intuition about the distinct effects of very high intravenous doses has been validated by modern research. While definitive evidence from large randomized trials demonstrating a clear survival benefit is lacking, intravenous vitamin C remains a subject of experimental investigation.
Current consensus holds that high-dose intravenous vitamin C should only be used within clinical trials or under strict medical supervision, not as a commercial immune booster.
The scientific understanding of vitamin C’s interaction with cancer continues to evolve. The history of vitamin C in cancer treatment reflects a complex path: initial enthusiasm, skepticism following inconclusive trials, and a cautious resurgence of research interest. Pauling’s early work, despite its flaws, anticipated some of the biological mechanisms now under study.
